Skip Navigation



Carcinogenesis Advance Access published online on January 12, 2008
Carcinogenesis, doi:10.1093/carcin/bgn008
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
29/2/411    most recent
bgn008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Tang, L.
Right arrow Articles by Wang, J.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tang, L.
Right arrow Articles by Wang, J.-S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Modulation of Aflatoxin Biomarkers in Human Blood and Urine by Green Tea Polyphenols Intervention

Lili Tang1, Meng Tang1, Li Xu1, Haitao Luo1, Tianren Huang2, Jiahua Yu2, Lisheng Zhang2, Weimin Gao1, Stephen B. Cox1 and Jia-Sheng Wang1,*

1 Department of Environmental Toxicology/The Institute of Environmental and Human Health, Texas Tech University, Lubbock, TX, 79409, USA
2 Guangxi Cancer Institute, Nanning, Guangxi, 530021, China

* Corresponding author: Dr. Jia-Sheng Wang, Box 41163, TIEHH/TTU, Lubbock, TX 79409-1163, Tel. 806-8850320 Fax. 806-8852132 E-mail: js.wang{at}ttu.edu

To evaluate the efficacy of green tea polyphenols (GTPs) in modulating aflatoxin B1 (AFB1) biomarkers, a total of 352 serum samples and 352 urine samples collected from a 3-month chemoprevention trial with 500 mg GTPs, 1,000 mg GTPs, and a placebo were measured for AFB1-albumin adducts (AFB-AA), AFM1, and AFB1-mercapturic acid (AFB-NAC). Levels of AFB-AA at baseline were comparable for all three dose groups (p = 0.506). No significant differences were observed in AFB-AA levels in the placebo group over the 3-month period (p = 0.252). However, a significant reduction in AFB-AA levels was observed in the 500 mg group (p = 0.002). A marginally significant reduction in AFB-AA levels was also found in the 1,000 mg group over the 3-month intervention period (p = 0.051). An analysis using a mixed-effects model indicated that the reduction in AFB-AA levels over time was dose and time dependent (dose-time interaction p = 0.049). There were no significant differences in median AFM1 levels among the three study groups at the baseline (p = 0.832), 1-month (p = 0.188), and 3-months (p = 0.132) of the GTP intervention; however, reduction of 42% and 43% in median AFM1 levels, as compared to the placebo, were found in 500 mg (p = 0.096) and 1,000 mg (p = 0.072) groups at 3-months of the intervention. Significant elevations in median AFB-NAC levels and the ratio AFB-NAC/AFM1 were found in both 500 mg and 1,000 mg groups compared to the placebo group at both 1-month (p<0.001) and 3-months (p<0.001) of GTPs intervention. These results demonstrate that GTPs effectively modulate AFB1 metabolism and metabolic activation.

Received August 28, 2007; revised December 28, 2007; accepted January 2, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.